What Is The Current and Historic Market Size Analysis Of The Non invasive Prenatal Testing Market?
The non invasive prenatal testing market has seen considerable growth due to a variety of factors.
• In the past few years, there has been a quick expansion in the non-invasive prenatal testing market. It is projected to increase from $5.48 billion in 2024 to $6.28 billion in 2025, with a compound annual growth rate (CAGR) of 14.7%.
Factors such as enhanced precision, diminished risks, higher maternal age, expanding consciousness, and clinical guidelines have contributed significantly to the growth during the historic period.
What are the Market Size and Expected Growth Rates for the Non invasive Prenatal Testing Market?
The non invasive prenatal testing market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, the non-invasive prenatal testing market is anticipated to experience a swift expansion. The market value is projected to reach $10.95 billion by 2029, growing at a compound annual growth rate (CAGR) of 14.9%.
The significant growth during the forecast period can be attributed to a variety of factors, including increased testing options, improved accessibility, the growing age of mothers, the detection of fetal anomalies, and the use of telemedicine and digital health advancements. The forecast period will also witness specific trends such as more comprehensive test panels, wider uptake of non-invasive prenatal tests (nipt), advanced technology, and non-invasive fetal aneuploidy (nifad) diagnosis.
Which Key Drivers Are Propelling The Non invasive Prenatal Testing Market's Growth?
The rise in the prevalence of Down syndrome is a significant driver of the non-invasive prenatal testing market, fueled by an increase in the average maternal age, raising concerns about the fetus's wellbeing. Down syndrome results from a chromosomal abnormality where error in cell division delivers an extra 21st chromosome, thus impacting the fetus's intellectual capacity and physical growth. The non-invasive prenatal tests (NIPT) pose no risk to the mother or infant, with no chances of miscarriage, and can identify over 99% of Down syndrome cases. Based on data from the National Down Syndrome Society and the Centres for Disease Control and Prevention, 1 in every 700 babies born in the US has Down syndrome, and 80% of these are to mothers of advanced age. The elevated probability of older women having children with Down syndrome propels the expansion of the non-invasive prenatal testing market.
What Are The Key Segments Within The Global Non invasive Prenatal Testing Market?
The non-invasive prenatal testing market covered in this report is segmented –
1) By Type: Consumables, Instruments
2) By Application: Trisomy, Microdeletion, Genetics, Rh factor
3) By End User: Hospital, Diagnostic Labs
Subsegment:
1) By Consumables: Assay Kits, Reagents, Disposables
2) By Instruments: Next-Generation Sequencers (NGS), Polymerase Chain Reaction (PCR) Systems, Ultrasound Devices, Others (Microarrays And Mass Spectrometers)
Pre-Book The Non invasive Prenatal Testing Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
What New Trends Are Influencing The Non invasive Prenatal Testing Market?
The advent of next-generation sequencing has significantly boosted the scalability, speed, and overall throughput, thus enabling scientists to execute a plethora of applications and delve deeper into biological systems. This platform permits sequencing of millions of DNA molecules simultaneously. Various manufacturing companies introduced this technology to minimize time and cost while maximizing the results related to genome and DNA testing. Prominent players like Illumina, Eurofins, Natera, Roche, and Annoroad have integrated this technology into their non-invasive prenatal testing procedures. Additionally, the China Food and Drug Administration (CFDA) has given the green light for the medical instrument product registration of the NGS instrument, NextSeq 550AR, produced by Annoroad.
Who Are the Key Players In The Non invasive Prenatal Testing Market?
Major companies operating in the non-invasive prenatal testing market include:
• F. Hoffmann-La Roche AG
• Illumina Inc.
• Laboratory Corporation of America Holdings
• Natera Inc.
• PerkinElmer Inc.
• Quest Diagnostics Inc.
• Agilent Technologies Inc.
• BGI Diagnosis Co Ltd.
• Berry Genomics Co
• LifeCodexx AG
• Myriad Genetics Inc.
• NIPD Genetics Co Ltd.
• Sequenom Inc.
• Annoroad Gene Technology Co Ltd.
• Centogene AG
• Counsyl Inc.
• EUROFINS Genoma Group
• Eurofins Scientific SE
• Next Biosciences
• Premaitha Health Plc
• Ariosa Diagnostics Inc.
• Beijing Genomics Institute
• Yourgene Health PLC
• GE Healthcare Technologies Inc.
• Koninklijke Philips NV
• Thermo Fisher Scientific Inc.
• Pacific Biosciences of California Inc.
• QIAGEN NV
• MedGenome Labs Ltd.
• Progenity Inc.
What Are The Regional Insights Into The Non invasive Prenatal Testing Market?
North America was the largest region in the non-invasive prenatal testing market in 2023. Western Europe was the second largest region in the non-invasive prenatal testing market. The regions covered in the non-invasive prenatal testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
